AgomAb Therapeutics NV (AGMB) vs Kyverna Therapeutics (KYTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AgomAb Therapeutics NV is the larger company by market cap ($454.1 million vs $382.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | KYTX |
|---|---|---|
| Share price | $9.22 | $6.18 |
| Market cap | $454.07M | $382.19M |
| 1-day change | +4.77% | +0.16% |
| YTD return | — | -34.26% |
| 1-year return | — | -13.93% |
| EPS (TTM) | $-2.08 | $-2.93 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $13.67 |
| 52-week low | $7.97 | $5.96 |
| Distance from 52-week high | -48.26% | -54.79% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +308.57% | +391.91% |
| Average volume | 139.21K | 903.83K |
| Shares outstanding | 49.25M | 61.84M |
| Employees | 62 | 149 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About Kyverna Therapeutics
KYTX stock →Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 149 employees
AGMB vs KYTX FAQ
Which is bigger, AgomAb Therapeutics NV or Kyverna Therapeutics?
AgomAb Therapeutics NV (AGMB) is larger, with a market capitalization of $454.07M compared with $382.19M for Kyverna Therapeutics (KYTX).
Are AgomAb Therapeutics NV and Kyverna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.